Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000996

Drug Information
NameMethoxsalen
SynonymsO-methylxanthotoxol; 8-Methoxy; 9-methoxyfuro[3,2-g]chromen-7-one; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; Xanthotoxine; NCGC00178871-02; Methoxsalen [BAN:JAN]; DivK1c_000763; ICN Brand 3 of Methoxsalen; New-Meladinin; Dermatech Brand of Methoxsalen; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; Methoxsalen plus ultraviolet radiation; 8 Methoxypsoralen; Meladinine; Oxoralen; Methoxalen; 8-methoxyfuranocoumarins; Methoxsalen Dermatech Brand; BRD-K63430059-001-06-5; CHEBI:18358; NCGC00178871-01; Methoxsalen (JP15/USP); BPBio1_000680; NCGC00060938-05; Oxsoralen lotion; NINDS_000763; SDCCGMLS-0042377.P002; A1783/0075596; 8-Methoxy-4',5':6,7-furocoumarin; BSPBio_001997; KBio2_006639; MEGxp0_000095; Ultramop; 8-methoxyfurocoumarins; Methoxsalen, 8-; CPD000071170; 9-Methoxyfuro(3,2-g)chromen-7-one; I06-0695; 8-MOP; OXSORALEN (TN); 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxypsoralene; Methoxsalen Delta Brand; 9-Methoxypsoralen; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; Delta Brand of Methoxsalen; Methoxsalen Sanofi-Synthelabo Brand; Uvadex; ACon1_000174; Zanthotoxin; NCGC00060938-04; Deltasoralen; 7H-Furo(3,2-G)(1)benzopyran-7-one, 9-methoxy-; Meloxine; KBioGR_000543; CHEBI:52028; SPECTRUM1500400; Oxsoralen; Methoxsalen with ultra-violet A theraphy; NCGC00060938-03; Spectrum_001023; Mex America Brand of Methoxsalen; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; BRN 0196453; SPBio_001004; Methoxaten; Methoxa-Dome; Ammoidin; CCRIS 2083; Ammodin; MolPort-000-696-480; CPD-13042; NCI-C55903; Mex-America Brand of Methoxsalen; 8MOP; D008730; C01864; Dermox; NCGC00178871-03; Psoralen-mop; 8-Methoxy-4',5',6,7-furocoumarin; SAM002548974; NCGC00060938-02; Methoxsalen Mex-America Brand; EINECS 206-066-9; 8-MP; 5-19-06-00015 (Beilstein Handbook Reference); Galderma Brand of Methoxsalen; ZINC02548959; Meladinina; Psoralon-MOP; 7-Furocoumarin; Proralone-mop; Spectrum2_001052; XANTHOTOXIN; S1952_Selleck; Oxsoralen Ultra; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8MO; 8-Methoxy-[furano-3'.2':6.7-coumarin]; DB Brand of Methoxsalen; Geroxalen; BRD-K63430059-001-03-2; HSDB 2505; Sanofi-Synthelabo Brand of Methoxsalen; 8-Methoxypsoralen; Oprea1_166319; KBio3_001497; 12692-94-3; X0009; KBio2_001503; KBio2_004071; NCGC00060938-06; MLS002303011; Ultra Mop; 8-Methoxyfuranocoumarin; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; Methoxy-8-psoralen; NSC45923; KBioSS_001503; an 8-methoxyfurocoumarin; Methoxsalen Canderm Brand; Prestwick_661; D00139; Oxsoralen-ultra; ICN Brand 1 of Methoxsalen; NCI60_004085; HMS502G05; HMS1920N05; ICN Brand 2 of Methoxsalen; CHEMBL416; M3501_SIAL; Puvamet; Prestwick0_000479; SPBio_002557; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; STOCK1N-03091; HMS2091D20; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; Oxsoralen Ul tra; Puvalen; 8-Methoxy-(furano-3'.2':6.7-coumarin); Prestwick3_000479; Methoxsalen Chinoin Brand; Boehringer Ingelheim Brand of Methoxsalen; Jsp005650; Meladinin (VAN); M3501_FLUKA; NCGC00016418-01; Chinoin Brand of Methoxsalen; BSPBio_000618; Ultramop Lotion; methoxsalen; AC-4259; Meladinin; Oxypsoralen; CID4114; WLN: T C566 DO LVOJ BO1; Spectrum3_000499; Meladoxen; MLS000062633; Prestwick1_000479; FT-0082222; Sanofi Synthelabo Brand of Methoxsalen; Methoxa Dome; DB00553; 8-Methoxy-2',3',6,7-furocoumarin; 8 MOP; STK735539; KBio1_000763; Spectrum4_000052; 298-81-7; HMS1569O20; AKOS000277012; Spectrum5_001891; LS-68; SMR000071170; Canderm Brand of Methoxsalen; UNII-U4VJ29L7BQ; CAS-298-81-7; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; AC1L1HFY; Prestwick2_000479; NSC 45923; 8-Methoxypsoralen with ultraviolet A therapy; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; IDI1_000763
Trade NameOxsoralen
IndicationPsoriasis
[ICD9: 696   ICD10: L40]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,
1H3
InChIKeyQXKHYNVANLEOEG-UHFFFAOYSA-N
Canonical SMILESCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 298-81-7
FormulaC12H8O4
PubChem Compound IDCID 4114.
PubChem Substance IDSID 4978.
ChEBI18358;
SuperDrug ATC IDD05AD02; D05BA02
SuperDrug CAS ID000298817;
TargetDNABinder[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009048 To Reference
Ref 2Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543